
Kymera Therapeutics, Inc. (NASDAQ:KYMR) has recently initiated dosing of patients in separate Phase 1 clinical trials evaluating its oncology drug candidates KT-333 and KT-413.
The KT-333 clinical trial includes patients with relapsed/refractory liquid and solid tumors, including T cell lymphomas and leukemia.